跳至主要内容
临床试验/NCT04752631
NCT04752631已完成4 期

MRI-guided thrOmbolysis for Stroke bEyond Time Window by TNK (ROSE-TNK): a Prospective, Randomized, Blinded Assessment of Outcome and Open Label Multi-center Study

General Hospital of Shenyang Military Region1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2021年3月9日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
80
试验地点
1
主要终点
Proportion of modified Rankin Scale (mRS) 0-1

研究概览

简要总结

This is an open label multicentre trial, evaluating the utility of MRI-guided thrombolysis for stroke beyond time window by Tenecteplase (TNK-tPA). This exploratory study was to describe the feasibility and outcome of thrombolytic therapy with TNK-tPA in 4.5-24 hours after stroke guided by a mismatch between diffusion-weighted imaging and FLAIR in the region of ischemia.

详细描述

In patients with acute stroke with an unknown time of onset, intravenous alteplase guided by a mismatch between diffusion-weighted imaging and FLAIR in the region of ischemia resulted in a significantly better functional outcome at 90 days. This trial will enroll acute ischemic stroke patients within 4.5 to 24 hours of onset. All the patients had an ischemic lesion that was visible on MRI diffusion-weighted imaging but no parenchymal hyperintensity on fluid-attenuated inversion recovery (FLAIR), which indicated that the stroke had a ischemic penumbra. Randomization will be 1:1 to TNK-tPA (experimental) or standard treatment (control), in compliance with guidelines for acute stroke. Clinical outcome was assessed by disability on the basis of the modified Rankin scale at 90 days follow-up, which will be performed by a blinded assessor.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

The Outcomes will be performed by a blinded assessor.

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient age 18-80 years;
  • The time from onset to treatment: 4.5-24 hours;
  • Acute Ischemic stroke confirmed by MRI;
  • NIHSS score :6-25, or NIHSS score≤ 5 but culprit vessel occlusion or severe stenosis ( ICA, MCA-M1/M2, ACA) on CTA/MRA;
  • Imaging requirements: (1) DWI infarct region: no more than 1/3 of middle cerebral artery territory or 1/2 of the anterior cerebral artery territory or 1/2 of the posterior cerebral artery territory; (2) DWI infarct volume <70 ml; (2) presence of DWI/Flair mismatch: DWI high signal and Flair visually normal;
  • the first onset of ischemic stroke or previous stroke with no obvious sequelae (mRS≤1);
  • Signed informed consent

排除标准

  • Planned endovascular treatment;
  • Serious neurological deficits before onset ( mRS ≥ 2);
  • Obvious head injuries or strokes within 3 months;
  • Subarachnoid hemorrhage;
  • History of intracranial hemorrhage;
  • Intracranial tumor, arteriovenous malformation or aneurysm;
  • Intracranial or spinal cord surgery within 3 months;
  • Arterial puncture at a noncompressible site within the previous seven days;
  • Active internal hemorrhage;
  • coagulation abnormalities: platelet count of <100000/mm3 ;
  • Aortic arch dissection;
  • Heparin therapy within 24 hours;
  • Infective endocarditis;
  • Oral warfarin is being taken and INR>1.6 or APTT abnormal;
  • oral anticoagulation therapy;
  • Systolic pressure ≥185 mmHg or diastolic pressure ≥110 mmHg;
  • Blood glucose < 50 mg/dl (2.7mmol/L);
  • Neurological deficit after epileptic seizures;
  • Major surgery within 1 month;
  • Gastrointestinal or urinary tract hemorrhage within the previous 30 days;
  • Myocardial infarction within 3 months;
  • allergy to study drugs;
  • Contradictory to MRI examination;
  • MRI image not qualified for evaluation;
  • Other serious illness;
  • Participating in other clinical trials within 3 months;
  • patients not suitable for this clinical studies considered by researcher.

研究组 & 干预措施

TNK-tPA

Experimental

TNK-tPA (0.25mg/kg) given as a single bolus over 5-10 seconds immediately upon randomization.

干预措施: Tenecteplase (Drug)

结局指标

主要结局

Proportion of modified Rankin Scale (mRS) 0-1

时间窗: 90 Days

the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome

次要结局

  • vascular events(90 Days)
  • Changes in National Institute of Health stroke scale (NIHSS)(24 hours and 1 week)
  • Proportion of modified Rankin Scale (mRS) 0-2(90 Days)
  • Distribution of the modified Rankin Scale (mRS)(90 Days)
  • proportion of death(14 days)

研究者

发起方
General Hospital of Shenyang Military Region
申办方类型
Other
责任方
Principal Investigator
主要研究者

Hui-Sheng Chen

Director of neurology department

General Hospital of Shenyang Military Region

研究点 (1)

Loading locations...

相似试验

已完成
3 期
Efficacy and Safety of MRI-based Thrombolysis in Wake-up StrokeStroke
NCT01525290Universitätsklinikum Hamburg-Eppendorf501
终止
4 期
Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and AtherothrombosisIschemic StrokeAtherothrombosisAtrial Fibrillation
NCT03062319National Hospital Organization Osaka National Hospital321
进行中(未招募)
1 期
A trial comparing clot-busting (thrombolytic) drug treatment against placebo for emergency treatment of acute stroke caused by a blocked brain blood vessel in patients in whom the time of onset is not known, using MRI scans to determine likely onset of stroke within the standard time allowed for clot-busting treatmentPatients with acute ischemic stroke proven by MRI and unknown time from symptom onset which otherwise fulfil the approval criteria for intravenous thrombolysis in acute strokeMedDRA version: 15.0Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2011-005906-32-GBniversity Medical Center Hamburg-Eppendorf800
进行中(未招募)
1 期
WAKE-UPPatients with acute ischemic stroke proven by MRI and unknown time from symptom onset which otherwise fulfil the approval criteria for intravenous thrombolysis in acute strokeMedDRA version: 18.0Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2011-005906-32-BEniversity Medical Center Hamburg-Eppendorf800
进行中(未招募)
1 期
Efficacy and safety of MRI-based thrombolysis in wake-upstroke
EUCTR2011-005906-32-DEniversity Medical Center Hamburg-Eppendorf800